Nrf2 Orchestrates Fuel Partitioning for Cell Proliferation  by Hayes, John D. & Ashford, Michael L.J.
Cell Metabolism
Previewsmicrobial opioids, or facilitate conversion
of alimentary oligopeptides into potent
MOR ligands? Microbial MOR agonists
have been identified before, such as the
ultrapotent dermorphins or deltorphins,
opioid agonists up to 40 times more
potent than morphine that have been iso-
lated from the skin of giant leaf frogs of
the genus Phyllomedusa. Albeit highly
speculative, such a potential interaction
of our gut flora and the nutropioid gut-
brain circuitry could add interesting future
perspectives to an already fascinating
research field.
The work by Duraffourd et al. (2012)
may not replace the currently accepted,
classical model of opioidergic food
intake control, which suggests the central
release of endogenous opioids as themajor stimulus for a hedonic drive to
consume food. Nonetheless, Duraffourd
et al. (2012) expand a CNS-centric view
to a model that also allows direct
peripheral action of alimentary opioid
antagonists on periportal MORs, followed
by the (IGP-dependent) decrease in food
consumption. The strength of this new
model lays in the integration of both
worlds; direct effects of alimentary ‘‘nu-
tropioids’’ could be followed by—or
compete—with a concomitant increase
in endogenous opioids, such as b-endor-
phin (which could be released by both the
GI tract and the CNS). Thus, exogenous
and endogenous opioids could orches-
trate hedonic feedingmechanisms atmul-
tiple sites, both in the periphery and in
the CNS.Cell Metabolism 1REFERENCES
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Why upregulation of the transcription factor Nrf2 increases tumor cell proliferation is unclear. Mitsuishi et al.
(2012) now provide evidence that Nrf2 augments purine nucleotide synthesis, thus supporting tissue hyper-
trophy. This change in cellular metabolism requires loss of Nrf2 repression by Keap1 as well as costimulation
via the PI3K-Akt pathway.NF-E2 p45-related factor 2 (Nrf2, also
called Nfe2l2) is a cap ‘n’ collar (CNC)
basic-region leucine zipper (bZIP) tran-
scription factor that allows cells to adapt
to oxidative stress and electrophiles by
mediating induction of a battery of cyto-
protective genes, including those encod-
ing enzymes involved in the synthesis
of reduced glutathione (GSH), repair of
oxidized protein thiols, scavenging of
reactive oxygen species (ROS), and
drug metabolism (Hayes et al., 2010).
The stress-responsive activity of Nrf2 is
dictated at the level of protein stability,
which is controlled by the ubiquitin
ligase substrate adaptor Kelch-like ECH-associated protein (Keap1). In normal
unstressed cells, Nrf2 protein is rapidly
turned over in a Keap1-dependent
manner through Cul3-Rbx1 ubiquitylation
and proteasomal degradation. However,
Keap1 is inactivated by ROS and electro-
philes, and such agents stabilize Nrf2
protein and cause induction of Nrf2-
target genes (McMahon et al., 2010). By
contrast with normal cells, Nrf2 protein
is constitutively upregulated in many
tumors due to somatic mutations in the
Keap1 or Nrf2 genes. Tumors that over-
express Nrf2 exhibit increased resistance
to chemotherapeutic drugs and higher
rates of proliferation (Zhang et al., 2010),though it is unclear why the latter occurs.
It has been suggested that Nrf2 might
increase phosphorylation of retinoblas-
toma protein and prevent cell-cycle arrest
(Homma et al., 2009) or that Nrf2 might
allow tumors to survive the high levels
of ROS that K-Ras, B-Raf, and Myc
oncogenes produce (DeNicola et al.,
2011). Given that cancer cells are
subject to metabolic reprogramming to
support rapid synthesis of macromole-
cules (Ward and Thompson, 2012), it is
also possible that Nrf2 promotes tumor
cell proliferation by influencing interme-
diary metabolism. In a recent, ground-
breaking study, Mitsuishi et al. (2012)6, August 8, 2012 ª2012 Elsevier Inc. 139
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Figure 1. Metabolic Pathways and Their Regulation in Proliferating Cells by the
Transcription Factor Nrf2
The diagram depicts the relationship between glycolysis, the TCA cycle, the pentose phosphate
pathway, glutamine metabolism, and glutathione synthesis. It also indicates, with a solid arrow or a
dashed arrow, respectively, genes that are directly or indirectly regulated by Nrf2. The inclusion of a
dashed arrow from PI3K to Nrf2 indicates that activation of the PI3K-Akt pathway substantially
augments induction of metabolic genes by the CNC-bZIP factor, though the mechanism has not
been established. As shown, Nrf2 controls the expression of glucose-6-phosphate dehydrogenase
(G6PD) and phosphogluconate dehydrogenase (PGD) in the oxidative arm of the pentose phosphate
pathway, as well as transaldolase 1 (TALDO1) and transketolase (TKT) in the nonoxidative arm of the
pentose phosphate pathway. In addition, Nrf2 regulates malic enzyme 1 (ME1) and isocitrate dehydro-
genase 1 (IDH1), which generate NADPH to support synthesis of macromolecules. It also regulates
the expression of glutamate-cysteine ligase catalytic (GCLC) and modifier (GCLM) subunits, which
together combine to catalyze the rate-limiting step in glutathione synthesis. Both ME1 and GCLC-
GCLM contribute to the utilization of glutamine in cancer cells. Lastly, Nrf2 indirectly regulates phos-
phoribosyl pyrophosphate amidotransferase (PPAT, also known as amidophosphoribosyltransferase
[ATase] or glutamine phosphoribosylpyrophosphate amidotransferase [GPAT]) and methylenetetrahy-
drofolate dehydrogenase 2 (MTHFD2) that are involved in purine synthesis. Abbreviations: G-6-P,
glucose-6-phosphate; F-6-P, fructose-6-phosphate; F-1,6-BP, fructose-1,6-bisphosphate; G-3-P, glyc-
eraldehyde-3-phosphate; 3-PG, 3-phosphoglycerate; PEP, phosphoenolpyruvate; 6-P-GL, 6-phospho-
gluconolactone; 6-PG, 6-phosphogluconate; R-5-P, ribulose-5-phosphate; 5-PRA, 5-phosphoribosyl-
amine; IMP, inosine monophosphate.
Cell Metabolism
Previewsshow that Nrf2 orchestrates profound
metabolic changes by directing glucose
and glutamine along anabolic pathways
that augment purine synthesis and
demonstrate that its influence on the
pentose phosphate pathway (PPP) con-
tributes to cell proliferation.
Human lung A549 cells constitutively
overexpress Nrf2 because they harbor
mutant Keap1 (Singh et al., 2006).
Following knockdown of Nrf2 in A549
cells, Mitsuishi et al. (2012) find, using
microarray analysis, that Nrf2 regulates
the expression of all four enzymes res-
ponsible for NADPH synthesis (G6PD,
PGD, ME1, and IDH1), consistent with140 Cell Metabolism 16, August 8, 2012 ª201the notion that Nrf2 activity supports syn-
thesis of macromolecules (Figure 1). Of
interest, G6PD and PGD catalyze reac-
tions in the oxidative arm of the PPP,
and the finding by Mitsuishi et al. (2012)
that Nrf2 also regulates TKT and
TALDO1, which catalyze reactions in the
nonoxidative arm of the PPP, suggests
the transcription factor represents a
dominant controller of metabolic flux
through the PPP. Lastly, Nrf2 increases
expression of the nucleotide synthesis
enzymes PPAT and MTHFD2. ChIP-Seq
analyses indicate that the G6PD, PGD,
ME1, IDH1, TKT, and TALDO1 genes
are regulated directly by Nrf2, whereas2 Elsevier Inc.PPAT and MTHFD2 are regulated indi-
rectly. Consistent with the microarray
and ChIP-Seq data, metabolomic experi-
ments indicate that upregulation of Nrf2
shifts glucose metabolism from glycol-
ysis toward purine nucleotide synthesis.
Thus, knockdown of Nrf2 in A549 cells
increases the levels of both glycolytic
and PPP intermediates while decreasing
intermediates involved in purine syn-
thesis. Furthermore, tracer studies indi-
cated that upregulation of Nrf2 augments
utilization of glutamine by increasing GSH
synthesis as a consequence of inducing
glutamate-cysteine ligase (GCL, which
comprises GCLC and GCLM subunits)
and by increasing the decarboxylation
of malate as a consequence of inducing
ME1 (Figure 1).
Mitsuishi et al. then test the hypo-
thesis that constitutive upregulation of
Nrf2 in tumors increases cell proliferation
because the transcription factor redi-
rects glucose metabolism from glycolysis
through the PPP to purine synthesis.
Using siRNA knockdown, the authors
show that loss of G6PD and TKT greatly
impedes growth of A549 cells in xenograft
experiments. Moreover, forced expres-
sion of Nrf2 in 293T cells increases their
rate of proliferation, and this can be reca-
pitulated by expression of ectopic G6PD
or TKT. Thus, cell proliferation that ac-
companies upregulation of Nrf2 appears,
at least in part, to be due to increased
G6PD and TKT activity.
Mitsuishi et al. (2012) find that glucose
metabolism also shifts toward purine
nucleotide synthesis in immortalized
Keap1 null mouse embryonic fibroblasts,
raising the question of whether upregula-
tion of Nrf2might support cell proliferation
in nontransformed tissues as well as in
tumors. Comparison of wild-type mice
and those with low levels of Keap1 (i.e.,
Keap1loxP/ mice) revealed that G6pd,
Tkt, Taldo1, Pgd, and Me1 are signifi-
cantly overexpressed in the forestomach
of the mutant animals, whereas no signif-
icant change was observed in the liver.
Furthermore, the increased expression
of these Nrf2-target genes in the forest-
omach of Keap1loxP/ mice is associated
with increased epithelial cell proliferation,
leading to hypertrophy. As forestomach
epithelial cells normally turnover rapidly,
whereas hepatocytes are normally quies-
cent, it seems likely that loss of Keap1
activity per se is not sufficient to redirect
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Previewsglucose metabolism through the PPP to
purine synthesis. Mitsuishi et al. (2012)
therefore argue that a proliferative signal
provided by the PI3K-Akt pathway is
required to increase flux through the
PPP in an Nrf2-dependent fashion and
provide evidence that Akt is activated
in mouse forestomach. The idea that
increased PI3K-Akt signaling in the liver
allows Nrf2 to induce G6pd, Tkt, Taldo1,
Pgd, and Me1 was confirmed by making
liver-specific Pten and Keap1 double-
knockout mice.
In summary, Mitsuishi et al. show that
under the direction of PI3K-Akt signaling,
Nrf2 regulates the expression of genes
involved in the PPP, generation of NADPH,
and synthesis of purine nucleotides. They
have expanded our knowledge of Nrf2
functions from increasing cytoprotection
to the regulation of metabolism and the
synthesis of macromolecules, thereby
providing an explanation of how Nrf2
supports cell proliferation. A number of
critical issues remain unresolved. The
mechanism by which Nrf2-mediated
induction of metabolic genes requires
both inhibition of Keap1 and activation of
PI3K-Akt, as opposed to induction of anti-
oxidant and detoxication genes, whichrequires only inhibition of Keap1, is
unclear. It is also not known how Nrf2
cooperateswith other transcription factors
implicated in metabolic reprogramming in
tumor cells, including p53, Myc, and
HIF1a (Kroemer and Pouyssegur, 2008;
Ward and Thompson, 2012), to maintain
high rates of glycolysis and increase cell
proliferation. It remains to be established
whether activation of Nrf2 along with the
PI3K-Akt pathway is sufficient to promote
carcinogenesis. Lastly, while inhibition of
Nrf2 as a cancer chemotherapeutic
strategy is an attractive proposition, it
may be unwise to reduce PPP metabolic
flux, given that the pathway provides an
important defense for neurons and astro-
cytes against oxidative damage and
neuronal death (Fernandez-Fernandez
et al., 2012). Accordingly, it is becoming
clear that Nrf2, in combination with growth
factorsignaling,providesacritical interface
between oxidative stress sensing and
metabolic reprogramming of cells.
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The mitochondrial pyruvate carrier (MPC) is essential for several major pathways of carbohydrate, fat, and
amino acidmetabolism, yet its molecular identity has remained elusive. Two recent papers in Science (Herzig
et al., 2012; Bricker et al., 2012) implicate three newly identified inner mitochondrial membrane proteins as
MPC components.Pyruvate lies at the heart of carbohydrate,
fat, and amino acid metabolism and is
usually produced in the cytoplasm before
being transported into the mitochondria
for further metabolism (Figure 1). Trans-
port is mediated by the mitochondrial
pyruvate carrier (MPC) whose existencewas confirmed in 1974 by the discovery of
a potent and specific inhibitor, a-cyano-4-
hydroxycinnamate (CHC). Subsequently,
its substrate and inhibitor specificity and
roles in metabolism were extensively in-
vestigated (Halestrap et al., 1980). Trans-
port of most metabolites across the innermitochondrial membrane (IMM) involves
members of the mitochondrial carrier
family (MCF; 53 members in humans),
which are usually 30–35 kDa in size
and have six transmembrane domains
(TMDs) (Palmieri and Pierri, 2010). In
1981 the CHC analog UK5099 (Ki 5 nM)6, August 8, 2012 ª2012 Elsevier Inc. 141
